SRF617 + etrumadenant + zimberelimab
Phase 2Terminated 2 views this week 0 watching💤 Quiet
Interest: 17/100
17
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Castration-resistant Prostate Cancer
Conditions
Metastatic Castration-resistant Prostate Cancer, Prostate Cancer
Trial Timeline
Jan 17, 2022 → Apr 5, 2023
NCT ID
NCT05177770About SRF617 + etrumadenant + zimberelimab
SRF617 + etrumadenant + zimberelimab is a phase 2 stage product being developed by Coherus BioSciences for Metastatic Castration-resistant Prostate Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT05177770. Target conditions include Metastatic Castration-resistant Prostate Cancer, Prostate Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Castration-resistant Prostate Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
12
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05177770 | Phase 2 | Terminated |
Competing Products
20 competing products in Metastatic Castration-resistant Prostate Cancer